Ferring’s Nocdurna Nixed By FDA Panel, But Gets Multiple Paths Forward
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee members recommend Ferring conduct new pre-approval study to demonstrate clinical meaningful benefit of nocturia treatment, offering up variety of possible study designs.